Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Bonus Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Share Price: GBP 15.15 per share.
- Transaction Type: Increase in interest in Ordinary Shares via dividend re-investment.
- Dividend Date: July 6, 2006.
Material Changes
The filing reports an increase in shareholdings for specific individuals under the SmithKline Beecham Bonus Investment Plan following the re-investment of dividends paid on July 6, 2006. No material changes to the company's overall financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a specific transaction in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares acquired by Mr. R Bondy and other plan participants, as the specific quantity for Mr. Bondy is truncated in the source text.
- Confirm the total dividend payout amount for the July 6, 2006 distribution to understand the scale of the re-investment.
- Check subsequent filings for any broader financial results or strategic updates not contained in this transaction-specific notice.